Ginkgo biloba has been marketed for decades as a “brain herb”—a natural cognitive enhancer said to sharpen memory, attention, and mental clarity.

In modern clinical research, however, ginkgo is less often studied as a day-to-day performance booster and more as a treatment candidate for age-related cognitive decline: mild cognitive impairment (MCI), mild dementia, vascular cognitive impairment, and cognitive problems after stroke.

The result is a literature with some encouraging signals, some large null results, and a recurring theme: outcomes depend heavily on which ginkgo product is used, who takes it, and what you measure.

Ginkgo Extract: EGb 761

Most clinical trials that report neurological or cognitive effects use a standardized leaf extract—especially EGb 761, typically formulated to contain 24% flavonoid glycosides and 6% terpene lactones, while keeping potentially irritating ginkgolic acids very low (often <5 ppm).

This matters because over-the-counter supplements can vary widely in composition and dose, making “ginkgo” studies difficult to compare and real-world results harder to predict.

Mechanistically, EGb 761 is often framed as a multi-target intervention: influencing oxidative stress and inflammation, supporting mitochondrial function, and altering cerebral blood flow and blood viscosity—pathways plausibly relevant to neurodegeneration and vascular brain injury.

These proposed mechanisms are biologically plausible, but plausibility is not efficacy; clinical outcomes still need to be demonstrated in well-controlled trials.

Mild Dementia

A 2025 meta-analysis focused specifically on patients with mild dementia pooled data from 4 randomized placebo-controlled trials (total n=782) using EGb 761 at 240 mg/day. Across these trials, ginkgo performed better than placebo on multiple clinically meaningful domains. (Riepe & Burkart 2025)

Some of the most concrete numbers come from the forest plots provided with the report:

• Cognition (SKT total score): pooled mean difference −1.91 points (95% CI −3.73 to −0.09, p≈0.04), favoring EGb 761. (Riepe & Burkart 2025)
• Global clinical assessment: pooled standardized mean difference (SMD) −0.78 (95% CI −1.41 to −0.15, p≈0.01). (Riepe & Burkart 2025)
• Activities of daily living (ADL): pooled SMD −0.59 (95% CI −1.07 to −0.12, p≈0.01). (Riepe & Burkart 2025)

(Interpreting signs can be confusing because scales differ; the key point is that the pooled direction favored EGb 761 in these analyses.)

A separate 2025 pooled analysis looked at a clinically important subgroup: people with dementia plus a history of cerebral infarction confirmed by imaging.

In 488 patients across four randomized trials, 240 mg/day EGb 761 was associated with statistically significant benefits versus placebo for cognition (p=0.0467), ADL (p=0.0230), and global clinical impression (p=0.0371), with adverse-event rates comparable to placebo. (Feng et al. 2025)

Taken together, these findings align with the idea that ginkgo’s best-supported “nootropic” niche may not be boosting already-healthy brains, but supporting cognition and function when vascular and neurodegenerative stressors are already present.

Mild cognitive impairment

MCI sits between normal aging and dementia, and it’s a tempting target: intervene early enough, and maybe you can slow decline. But the evidence base includes a mixture of randomized trials, pragmatic studies, and retrospective analyses.

One open-access real-world study of amnestic MCI followed 133 memory-clinic patients over 12 months and compared three groups: EGb 761 alone (n=54), acetylcholinesterase inhibitors (AChEI) alone (n=31), and combined EGb 761 + AChEI (n=48). The combined group improved the most on several cognitive measures:

• MMSE change (baseline to 12 months):
  • EGb 761: +1.84 ± 0.14
  • AChEI: +2.48 ± 0.17
  • EGb 761 + AChEI: +4.23 ± 0.79 (García-Alberca et al. 2022)
• Memory (RAVLT) change: EGb 761 + AChEI +3.42 ± 0.56, versus ~+1.22 (EGb 761) and +1.29 (AChEI). (García-Alberca et al. 2022)
• Neuropsychiatric symptoms (NPI): compared with AChEI alone at 12 months, the combined group differed by −3.71 points (95% CI −6.50 to −0.93, p=0.005). (García-Alberca et al. 2022)

Safety in that study was acceptable, with “possibly related” adverse events reported in 28.7% (EGb 761), 46.1% (AChEI), and 48.2% (combined), and no serious adverse events recorded. (García-Alberca et al. 2022)

The catch: this was retrospective rather than a blinded randomized trial, so it can’t fully rule out selection effects (who got what treatment and why).

Still, it adds to a pattern seen across multiple clinical contexts: improvements are often more visible in memory and executive-function-heavy outcomes, and sometimes in neuropsychiatric symptoms, than in broad “global cognition” measures.

Post-stroke cognition

Stroke is a major risk factor for later cognitive decline. A 2023 multicenter randomized trial studied 201 adults ≥50 with mild-to-moderate ischemic stroke over 24 weeks, comparing EGb 761 (240 mg/day) with a reference/standard-care group. The primary headline result was on MoCA (a global cognitive screening test):

• MoCA change: +2.92 with EGb 761 vs +1.33 in the reference group
• Between-group difference: +1.59 points (95% CI 0.51 to 2.67; p < 0.005) (Cui et al. 2023)

Secondary measures also leaned in ginkgo’s favor for specific domains:

• Hopkins Verbal Learning Test Total Recall: +1.40 (EGb 761) vs −0.49 (reference)
• Shape Trail Test Form 1: −38.2 vs −15.6 (more negative indicating larger improvement in time-based performance) (Cui et al. 2023)

Adverse events were similar between groups: 11.1% of EGb 761 patients vs 9.9% reference patients had at least one adverse event during the 24-week period. (Cui et al. 2023)

This kind of result fits a cautious “nootropic” framing: not a dramatic cognitive lift, but a modest, measurable improvement over months in a population at risk.

Alzheimer’s disease

A 2025 retrospective study examined amyloid PET-positive Alzheimer’s patients over 12 months, comparing donepezil alone (n=60) versus donepezil + ginkgo (n=41). The ginkgo-adjunct group showed:

• K-MMSE: +2.4 improvement at 12 months in the donepezil-ginkgo group
• Plasma MDS-Oaβ: −0.15 reduction (a biomarker linked to amyloid oligomerization propensity)
• CDR-SB: no significant between-group difference (Yang et al. 2025)

This is interesting because it pairs cognitive change with a biomarker shift, but it’s still not a substitute for large, blinded randomized trials—especially when functional outcomes don’t clearly separate.

If ginkgo is a cognitive enhancer, shouldn’t it prevent dementia? Two large, long-duration trials tested that idea—and largely came up empty.

In the Ginkgo Evaluation of Memory (GEM) trial, older adults received 120 mg twice daily EGb 761. Dementia incidence was not reduced:

• All-cause dementia hazard ratio: 1.12 (95% CI 0.94–1.33, p=0.21)
• Alzheimer’s disease hazard ratio: 1.16 (95% CI 0.97–1.39, p=0.11)
• Progression to dementia in MCI subgroup: HR 1.13 (95% CI 0.85–1.50, p=0.39) (DeKosky et al. 2008)

A meta-analysis combining the two major prevention trials (total 5,889 participants) similarly found no difference in dementia rates: OR 1.05 (95% CI 0.89–1.23). (Charemboon et al. 2015)

So, the best supported claim is not “ginkgo prevents dementia,” but rather that some standardized extracts may provide modest symptomatic benefit in certain diagnosed populations.

Meta-analyses disagreement

A striking example: a 2026 systematic review/meta-analysis including studies from 2000–2025 concluded effects were small and clinically meaningless. For cognition measured by ADAS-Cog, the pooled result was:

• ADAS-Cog pooled SMD: 0.03 (95% CI −0.27 to 0.33), I²=80%
• ADL pooled SMD: 0.02 (95% CI −0.17 to 0.21), I²=7% (Omar & Ghani 2026)

This doesn’t necessarily “cancel out” the more favorable 2025 mild-dementia subgroup analysis; it highlights how conclusions shift depending on inclusion criteria, outcome measures (ADAS-Cog vs SKT), patient mix (MCI vs established dementia), and trial quality.

In healthy adults

If your goal is sharper focus for exams or work, clinical research is comparatively thin. A 2025 network meta-analysis of 27 RCTs (2,334 participants) testing various natural extracts in healthy adults found no extract significantly outperformed placebo for attention, and the strongest rankings for memory/executive function were for a Cistanche + Ginkgo combination rather than ginkgo alone. (Wang et al. 2025)

That doesn’t prove ginkgo is useless for healthy cognition—but it does suggest that, as of the most recent syntheses, robust evidence for reliable cognitive enhancement in healthy people is not the main story.

Safety Profile

Across trials, EGb 761 is often described as well tolerated. A key concern is bleeding risk, especially with anticoagulants and antiplatelet drugs.

A controlled hemostasis study reported no evidence that EGb 761 increased bleeding risk or meaningfully altered coagulation markers; baseline vs week-26 differences were <1 unit for prothrombin/bleeding time and <0.1 for INR, and small warfarin subgroups did not suggest enhanced warfarin effect. (Kloft et al. 2021)

But real-world medication combinations remain worth caution. In a 2025 retrospective hospital analysis of 2,647 prescriptions, 12.94% involved a potential ginkgo drug interaction; among 747 patients evaluated for bleeding disorders, 4.15% (31 patients) had bleeding symptoms.

The presence of recorded ginkgo drug interactions correlated with bleeding risk (OR 1.08, p<0.001) and abnormal coagulation (OR 1.49, p<0.001), with common interacting drugs including aspirin and clopidogrel (each 2.61% prevalence among prescriptions). (Mai et al. 2025)

In practice: if someone is considering ginkgo while taking antiplatelets/anticoagulants—or before surgery—it’s a “talk to your clinician/pharmacist first” situation.

Ginkgo as a nootropic

• In diagnosed mild dementia and some vascular-related cognitive states, standardized ginkgo (notably EGb 761 at ~240 mg/day) shows modest average symptomatic benefits on cognition, global assessment, and daily function in several pooled analyses and trials. (Riepe & Burkart 2025; Cui et al. 2023; Feng et al. 2025)
• For preventing dementia, large high-quality trials are negative, with hazard ratios near 1.0 and confidence intervals crossing no effect. (DeKosky et al. 2008; Charemboon et al. 2015)
• For healthy adults seeking performance enhancement, the strongest recent evidence syntheses do not yet support a consistent attention or cognition boost from ginkgo alone. (Wang et al. 2025)

References

Riepe, M., & Burkart, M. (2025). Meta-analysis of Ginkgo biloba extract EGb 761 in the treatment of mild dementia. European Psychiatry, 68(Suppl 1), S863. https://doi.org/10.1192/j.eurpsy.2025.1749

Feng, J.-x., Zheng, M.-q., Tian, X., Zimmermann, A., Wang, A.-x., & Meng, X. (2025). Ginkgo biloba extract EGb 761 in patients with dementia and a history of cerebral infarction – meta-analysis of pooled data from randomised clinical trials. Frontiers in Neurology. https://doi.org/10.3389/fneur.2025.1658064

Cui, M., You, T., Zhao, Y., Liu, R., Guan, Y., Liu, J., Liu, X., Wang, X., & Dong, Q. (2023). Ginkgo biloba extract EGb 761® improves cognition and overall condition after ischemic stroke: Results from a pilot randomized trial. Frontiers in Pharmacology, 14, 1147860. https://doi.org/10.3389/fphar.2023.1147860

García-Alberca, J. M., Gris, E., & Mendoza, S. (2022). Combined treatment with Ginkgo biloba extract EGb 761 plus acetylcholinesterase inhibitors improved cognitive function and neuropsychiatric symptoms in patients with mild cognitive impairment. Alzheimer’s & Dementia: Translational Research & Clinical Interventions, 8(1), e12338. https://doi.org/10.1002/trc2.12338

Yang, Y., Koo, M.-S., & Kwak, Y. T. (2025). Efficacy of Ginkgo biloba as an adjunct to donepezil in amyloid PET-positive Alzheimer’s patients. Frontiers in Neurology, 16, 1563056. https://doi.org/10.3389/fneur.2025.1563056

Yang, Y. S., Koo, M.-S., & Kwak, Y. T. (2025). Efficacy of Ginkgo biloba extract in amyloid PET-positive patients with mild cognitive impairment. Frontiers in Neurology. https://doi.org/10.3389/fneur.2025.1639924

DeKosky, S. T., Williamson, J. D., Fitzpatrick, A. L., Kronmal, R. A., Ives, D. G., Saxton, J. A., et al. (2008). Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA, 300(19), 2253–2262. https://doi.org/10.1001/jama.2008.683

Charemboon, T., & Jaisin, K. (2015). Ginkgo biloba for prevention of dementia: a systematic review and meta-analysis. Journal of the Medical Association of Thailand, 98(5), 508–513. “https://pubmed.ncbi.nlm.nih.gov/26058281/
“

Omar, S. H., & Ghani, M. A. (2026). Cognitive and functional effects of Ginkgo biloba in neurodegenerative disorders: Systematic review and meta analysis. Pharmacological Research – Reports, 5, 100077. https://doi.org/10.1016/j.prerep.2026.100077

Wang, Z.-y., Deng, Y.-l., Zhou, T.-y., Liu, Y., & Cao, Y. (2025). Effects of natural extracts in cognitive function of healthy adults: a systematic review and network meta-analysis. Frontiers in Pharmacology. https://doi.org/10.3389/fphar.2025.1573034

Kloft, C., & Hoerr, R. (2021). EGb 761® Does Not Affect Blood Coagulation and Bleeding Time in Patients with Probable Alzheimer’s Dementia—Secondary Analysis of a Randomized, Double-Blind Placebo-Controlled Trial. Healthcare (Basel), 9(12), 1678. https://doi.org/10.3390/healthcare9121678

Mai, N. T. Q., Hieu, N. V., Ngan, T. T., Van Anh, T., Van Linh, P., & Thu Phuong, N. T. (2025). Impact of Ginkgo biloba drug interactions on bleeding risk and coagulation profiles: A comprehensive analysis. PLOS ONE, 20(4), e0321804. https://doi.org/10.1371/journal.pone.0321804